Come up with a name for your new list and we'll add to it:
Xdynia raised a round of funding on February 21, 2012. Investors include
CIT GAP Funds.
Xdynia is developing a class of compounds targeting the Cav 3.2 Ca++ channel, a common pathway in the development of neuropathic pain. These inhibitors are designed to alleviate common side-effects re…